Theracryf Plc (TCF) Ordinary 0.25p

Sell:0.23pBuy:0.25p0.01p (2.13%)

Prices delayed by at least 15 minutes
Sell:0.23p
Buy:0.25p
Change:0.01p (2.13%)
Deal now
Prices delayed by at least 15 minutes
Sell:0.23p
Buy:0.25p
Change:0.01p (2.13%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

TheraCryf plc is a clinical-stage drug development company focusing on brain disorders. The Company has a clinical and preclinical pipeline of indications, including addiction, anxiety, fatigue, narcolepsy, glioblastoma and neurodevelopmental disorders. Its lead program, orexin-1 antagonist, is being developed towards the clinic to target addictive behaviors like binge eating disorder (BED). It is also advancing a clinical-stage asset, SFX-01, in the fatal brain cancer glioblastoma (GBM). SFX-01 is a patented form of sulforaphane which has shown potential in the treatment of various cancers, neurodevelopmental disorders and other diseases. It has licensed the global rights for SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla. The Company also has a candidate molecule dopamine active transport (DAT) inhibitor at a late preclinical stage targeting fatigue and narcolepsy.

Key people

Huw Jones
Chief Executive Officer, Executive Director
Toni Markus Antero Haenninen
Chief Financial Officer, Director
Alastair Smith
Non-Executive Chairman of the Board
Edward Wardle
Non-Executive Director
Alan Barge
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    TCF
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    GB00BSVYN304
  • Market cap
    £5.16m
  • Employees
    9
  • Shares in issue
    2.15bn
  • Exchange
    London Stock Exchange (LON)
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.